Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
The mRNA synthesis and manufacturing market is projected to grow from USD 2.23 billion in 2024 to USD 2.96 billion by 2029 at a 5.8% CAGR. Consumables led in 2023, while Asia Pacific is expected to be the fastest-growing region.
Trump administration cuts to U.S. science funding have raised fears of a brain drain, with thousands of grants cancelled and researchers moving abroad. Experts warned the losses could damage biomedical innovation and the economy.
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
The National Institute of Allergy and Infectious Diseases has been instructed to remove "biodefense" and "pandemic preparedness" language from its website, signaling a major shift away from these research priorities. NIH leadership says the institute will now focus on current infectious diseases and basic immunology rather than predicting future threats. Public health experts warn this could leave the U.S. less prepared for future health emergencies.
Roche Holding AG shares show potential undervaluation despite strong returns, with DCF models suggesting 59% upside. The pharmaceutical giant trades at P/E ratios below fair value estimates while maintaining solid financial performance and dividend growth. Recent pipeline developments and product innovations support long-term growth prospects.
Moderna shares declined nearly 6% amid extreme options market volatility and a new patent infringement lawsuit from BioNTech. The company faces significant financial challenges with negative earnings and declining revenue growth, while valuation metrics suggest potential overvaluation. Technical indicators point to bearish short-term momentum as the stock approaches key support levels.
Origin Genomics launches to pursue germline gene editing research despite US prohibitions, while Thermo Fisher completes its $8.88 billion acquisition of Clario Holdings. Lucid Diagnostics reports Q4 revenue growth, and multiple partnerships form across the diagnostics and synthetic biology sectors.
U.S. overdose deaths declined 19% year-over-year to 72,108 for the 12 months ending September 2025, but the drug market is evolving with dangerous polydrug cocktails like "pink cocaine" and "rhino tranq" that are harder to detect and reverse. These synthetic blends combine fentanyl with stimulants, sedatives, and veterinary tranquilizers, creating new public health challenges as naloxone becomes less effective against complex overdoses.
BioVersys has dosed the first patient in a Phase 2b trial evaluating alpibectir-ethionamide (AlpE) in combination with first-line TB drugs, following promising Phase 2a results published in the New England Journal of Medicine.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07569172 |
Improved Child Nutrition and Development Through Social Transfers |
NOT_YET_RECRUITING | NA |
| NCT07406529 |
Fostering Prosocial Preventive Behaviours Through Awe |
RECRUITING | NA |
| NCT07347015 |
Prescription Support System for Antimicrobial Use in Belgian Primary Care |
RECRUITING | NA |
| NCT07176247 |
Real-world Multicentre Study of AZtreonam-AVIbactam Treatment With Infections or Suspected Infections Caused by Multidrug-resistant Gram-negative Bacteria |
ENROLLING_BY_INVITATION | |
| NCT07054320 |
Rapamycin and Infection-related Illness |
ACTIVE_NOT_RECRUITING | |
| NCT07048301 |
Omaha System-Based Health Application on Improving Knowledge, Attitude, and Behaviors Regarding Infectious Disease Prevention in the Community |
NOT_YET_RECRUITING | NA |
| NCT07029932 |
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Ascending Doses of BWC0977 in Healthy Volunteers |
RECRUITING | PHASE1 |
| NCT06864585 |
A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan |
NOT_YET_RECRUITING | |
| NCT06762002 |
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort |
RECRUITING | |
| NCT06722131 |
Biobank of Samples From Patients With Infectious Diseases |
NOT_YET_RECRUITING |
